AptarGroup, Inc. (ATR)
NYSE • Healthcare
Last close at October 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, AptarGroup, Inc. keeps $9 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 19 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
AptarGroup beat expectations on both the top and bottom line in the second fiscal quarter of 2026, based on preliminary results reported July 30, 2026. Revenue rose 6.3% to about $1.0 billion and came in 1.7% ahead of the $1.01 billion consensus, while adjusted EPS of $1.42 topped the $1.35 estimate by 5.2% even as it was down 14.5% from $1.66 a year ago. Net income fell 21.6% to about $88 million from $111.7 million a year earlier, and operating income reached about $126 million. The company generated about $119 million of operating cash flow, repurchased about $100 million of stock, and paid about $31 million in dividends. Consensus for the next period calls for EPS of $1.46 on revenue of $991.9 million.
Next report — what to expect
AptarGroup, Inc. (ATR) reports next on October 29, 2026. Wall Street is looking for EPS of $1.46 on revenue of $982.8 million. As trailing context, revenue rose +6.3% year over year last quarter. AptarGroup has beaten EPS in 8 of its 8 most recent quarters.
About AptarGroup, Inc.
AptarGroup, Inc. (NYSE: ATR) makes drug-delivery, dispensing, sealing, and materials solutions for healthcare and consumer packaged goods markets. In medical instruments and supplies, the company sells pharmaceutical critical components and broader dispensing systems across its portfolio, and recorded $3.8 billion of revenue in FY2025.
Today's Snapshot
ATR closed 1.2% lower at 120.38, against a firmer sector. AptarGroup received a Neutral rating as UBS, an investment bank, began evaluating its shares.
Trading Volume
Above 10d avg 520.5K
542.1K
vs S&P 500 Today
Underperforming Market
-1.76%
Updated: October 9, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$121.44 - $126.31Sell
- RSI (14)36.20Neutral
- Stochastic %K (14, 3, 3)29.26Neutral
- MACD Level (12, 26)-2.05Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.